Twin Tree Management LP Purchases Shares of 4,387 uniQure (NASDAQ:QURE)

Twin Tree Management LP purchased a new stake in uniQure (NASDAQ:QURE) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The fund purchased 4,387 shares of the biotechnology company’s stock, valued at approximately $77,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in QURE. Monaco Asset Management SAM bought a new stake in shares of uniQure in the 4th quarter valued at about $2,414,000. Raymond James Financial Inc. bought a new stake in shares of uniQure in the 4th quarter valued at about $1,951,000. Oppenheimer & Co. Inc. bought a new stake in shares of uniQure in the 4th quarter valued at about $320,000. Palumbo Wealth Management LLC bought a new stake in shares of uniQure in the 4th quarter valued at about $437,000. Finally, China Universal Asset Management Co. Ltd. raised its holdings in shares of uniQure by 9.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 11,062 shares of the biotechnology company’s stock valued at $195,000 after purchasing an additional 969 shares during the period. 78.83% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Christian Klemt sold 2,916 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $11.32, for a total transaction of $33,009.12. Following the completion of the sale, the chief financial officer now owns 155,168 shares of the company’s stock, valued at approximately $1,756,501.76. This represents a 1.84 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Matthew C. Kapusta sold 28,341 shares of the company’s stock in a transaction that occurred on Tuesday, March 4th. The stock was sold at an average price of $10.29, for a total transaction of $291,628.89. Following the sale, the chief executive officer now directly owns 651,454 shares of the company’s stock, valued at approximately $6,703,461.66. This trade represents a 4.17 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 90,830 shares of company stock worth $961,401 in the last quarter. Corporate insiders own 4.74% of the company’s stock.

uniQure Stock Performance

Shares of NASDAQ:QURE opened at $14.04 on Thursday. The company’s 50 day moving average price is $13.83 and its two-hundred day moving average price is $10.39. uniQure has a 12-month low of $3.73 and a 12-month high of $19.18. The firm has a market cap of $759.24 million, a PE ratio of -2.83 and a beta of 0.36. The company has a quick ratio of 6.51, a current ratio of 6.51 and a debt-to-equity ratio of 0.92.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on QURE. Guggenheim reaffirmed a “buy” rating on shares of uniQure in a report on Wednesday, December 11th. Stifel Nicolaus upped their target price on shares of uniQure from $12.00 to $32.00 and gave the company a “buy” rating in a report on Monday, December 16th. StockNews.com upgraded shares of uniQure to a “sell” rating in a research note on Tuesday, March 11th. Cantor Fitzgerald upped their price target on shares of uniQure from $28.00 to $58.00 and gave the company an “overweight” rating in a research note on Tuesday, December 10th. Finally, Leerink Partners upped their price target on shares of uniQure from $26.00 to $44.00 and gave the company an “outperform” rating in a research note on Wednesday, December 11th. One research analyst has rated the stock with a sell rating, three have issued a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, uniQure currently has a consensus rating of “Moderate Buy” and an average target price of $38.89.

uniQure Profile

uniQure N.V. develops treatments for patients suffering from rare and other devastating diseases. It offers HEMGENIX that has completed Phase III HOPE-B pivotal trial for the treatment of hemophilia B. The company also develops AMT-130, a gene therapy that is in Phase I/II clinical study for the treatment of Huntington's disease.